NAVIGATE ESUS Study Stopped Early Due to Comparable Efficacy in Treatment Arms

RARITAN, N.J., Oct. 5, 2017 /PRNewswire/ -- Janssen Research & Development, LLC and its development partner Bayer today announced the Phase III NAVIGATE ESUS study, evaluating the efficacy and safety of XARELTO(®) (rivaroxaban) for the secondary prevention of stroke and systemic embolism in patients with a recent embolic stroke of undetermined source (ESUS), is stopping early for futility. This decision is based on the recommendation of the study's Independent Data Monitoring Committee (IDMC) as the trial showed comparable efficacy between rivaroxaban and the standard of care, aspirin, and little chance of rivaroxaban showing an overall benefit versus aspirin if the study were to be completed. While bleeding rates were very low overall and within the expected range, an increase in bleeding was observed in the rivaroxaban arm compared to aspirin.

ESUS refers to patients with embolic stroke of unknown origin in whom common causes such as atrial fibrillation and carotid artery stenosis have been excluded. It is estimated to affect approximately 500,000 people in the United States annually.

"XARELTO(®) is a highly effective anticoagulant for patients at risk for stroke from atrial fibrillation, as well as for the prevention and treatment of clots in a variety of approved indications," said Paul Burton, MD, PhD, FACC, Vice President, Medical Affairs, Janssen. "Results from ROCKET AF and emerging real-world data continue to show the positive benefit of XARELTO(®) in preventing cardiovascular events, including stroke."

The Phase III NAVIGATE ESUS trial enrolled approximately 7,200 patients from 459 sites across 31 countries worldwide. In the study, patients were randomized to receive either rivaroxaban 15 mg once daily or aspirin 100 mg once daily alone. The primary efficacy endpoint was a composite of stroke and systemic embolism; the primary safety endpoint was major bleeding. A complete data analysis is expected to be presented in 2018.

WHAT IS XARELTO(®)?
XARELTO(®) is a prescription medicine used to reduce the risk of stroke and blood clots in people with atrial fibrillation, not caused by a heart valve problem. For patients currently well managed on warfarin, there is limited information on how XARELTO(®) and warfarin compare in reducing the risk of stroke.

XARELTO(®) is also a prescription medicine used to treat deep vein thrombosis and pulmonary embolism, and to help reduce the risk of these conditions occurring again.

XARELTO(®) is also a prescription medicine used to reduce the risk of forming a blood clot in the legs and lungs of people who have just had knee or hip replacement surgery.

IMPORTANT SAFETY INFORMATION

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT XARELTO(®)?

    --  For people taking XARELTO(®) for atrial fibrillation:People with atrial
        fibrillation (an irregular heart beat) are at an increased risk of
        forming a blood clot in the heart, which can travel to the brain,
        causing a stroke, or to other parts of the body. XARELTO(®) lowers your
        chance of having a stroke by helping to prevent clots from forming. If
        you stop taking XARELTO(®), you may have increased risk of forming a
        clot in your blood.Do not stop taking XARELTO(®) without talking to the
        doctor who prescribes it for you. Stopping XARELTO(®) increases your
        risk of having a stroke.If you have to stop taking XARELTO(®), your
        doctor may prescribe another blood thinner medicine to prevent a blood
        clot from forming.
    --  XARELTO(®) can cause bleeding, which can be serious, and rarely may
        lead to death. This is because XARELTO(®) is a blood thinner medicine
        that reduces blood clotting. While you take XARELTO(®) you are likely
        to bruise more easily and it may take longer for bleeding to stop.

You may have a higher risk of bleeding if you take XARELTO(®) and take other medicines that increase your risk of bleeding, including:

    --  Aspirin or aspirin-containing products
    --  Non-steroidal anti-inflammatory drugs (NSAIDs)
    --  Warfarin sodium (Coumadin(®), Jantoven(®))
    --  Any medicine that contains heparin
    --  Clopidogrel (Plavix(®))
    --  Selective serotonin reuptake inhibitors (SSRIs) or serotonin
        norepinephrine reuptake inhibitors (SNRIs)
    --  Other medicines to prevent or treat blood clots

Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above.

Call your doctor or get medical help right away if you develop any of these signs or symptoms of bleeding:

    --  Unexpected bleeding or bleeding that lasts a long time, such as:
        --  Nosebleeds that happen often
        --  Unusual bleeding from gums
        --  Menstrual bleeding that is heavier than normal, or vaginal bleeding
    --  Bleeding that is severe or that you cannot control
    --  Red, pink, or brown urine
    --  Bright red or black stools (looks like tar)
    --  Cough up blood or blood clots
    --  Vomit blood or your vomit looks like "coffee grounds"
    --  Headaches, feeling dizzy or weak
    --  Pain, swelling, or new drainage at wound sites

Spinal or epidural blood clots (hematoma): People who take a blood thinner medicine (anticoagulant) like XARELTO(®), and have medicine injected into their spinal and epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis). Your risk of developing a spinal or epidural blood clot is higher if:

    --  A thin tube called an epidural catheter is placed in your back to give
        you certain medicine
    --  You take NSAIDs or a medicine to prevent blood from clotting
    --  You have a history of difficult or repeated epidural or spinal punctures
    --  You have a history of problems with your spine or have had surgery on
        your spine

If you take XARELTO(®) and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots. Tell your doctor right away if you have back pain, tingling, numbness, muscle weakness, (especially in your legs and feet), or loss of control of the bowels or bladder (incontinence).

XARELTO(®) is not for patients with artificial heart valves.

WHO SHOULD NOT TAKE XARELTO(®)?
Do not take XARELTO(®) if you:

    --  Currently have certain types of abnormal bleeding. Talk to your doctor
        before taking XARELTO(®) if you currently have unusual bleeding.
    --  Are allergic to rivaroxaban or any of the ingredients of XARELTO(®).

WHAT SHOULD I TELL MY DOCTOR BEFORE OR WHILE TAKING XARELTO(®)?
Before taking XARELTO(®), tell your doctor if you:

    --  Have ever had bleeding problems
    --  Have liver or kidney problems
    --  Have any other medical condition
    --  Are pregnant or plan to become pregnant. It is not known if XARELTO(®)
        will harm your unborn baby. Tell your doctor right away if you become
        pregnant while taking XARELTO(®). If you take XARELTO(®) during
        pregnancy, tell your doctor right away if you have bleeding or symptoms
        of blood loss.
    --  Are breastfeeding or plan to breastfeed. It is not known if XARELTO(®)
        passes into your breast milk. You and your doctor should decide if you
        will take XARELTO(®) or breastfeed.

Tell all of your doctors and dentists that you are taking XARELTO(®). They should talk to the doctor who prescribed XARELTO(®) for you before you have any surgery, medical or dental procedure.

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements. Some of your other medicines may affect the way XARELTO(®) works. Certain medicines may increase your risk of bleeding. See "What is the most important information I should know about XARELTO(®)?"

Especially tell your doctor if you take:

    --  Ketoconazole (Nizoral(®))
    --  Itraconazole (Onmel((TM)), Sporanox(®))
    --  Ritonavir (Norvir(®))
    --  Lopinavir/ritonavir (Kaletra(®))
    --  Indinavir (Crixivan(®))
    --  Carbamazepine (Carbatrol(®), Equetro(®), Tegretol(®),
        Tegretol(®)-XR, Teril((TM)), Epitol(®))
    --  Phenytoin (Dilantin-125(®), Dilantin(®))
    --  Phenobarbital (Solfoton((TM)))
    --  Rifampin (Rifater(®), Rifamate(®), Rimactane(®), Rifadin(®))
    --  St. John's wort (Hypericum perforatum)

Ask your doctor if you are not sure if your medicine is one listed above. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

HOW SHOULD I TAKE XARELTO(®)?

Take XARELTO(®) exactly as prescribed by your doctor.

Do not change your dose or stop taking XARELTO(®) unless your doctor tells you to.

    --  Your doctor will tell you how much XARELTO(®) to take and when to take
        it.
    --  Your doctor may change your dose if needed.

If you take XARELTO(®) for:

-- Atrial Fibrillation: Take XARELTO(®) 1 time a day with your evening meal.If you miss a dose of XARELTO(®), take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time. -- Blood clots in the veins of your legs or lungs: -- Take XARELTO(®) once or twice a day as prescribed by your doctor. -- Take XARELTO(®) with food at the same time each day. -- If you miss a dose of XARELTO(®): -- and take XARELTO(®) 2 times a day: Take XARELTO(®) as soon as you remember on the same day. You may take 2 doses at the same time to make up for the missed dose. Take your next dose at your regularly scheduled time. -- and take XARELTO(®) 1 time a day: Take XARELTO(®) as soon as you remember on the same day. Take your next dose at your regularly scheduled time. -- Hip or knee replacement surgery: Take XARELTO(®) 1 time a day with or without food. If you miss a dose of XARELTO(®), take it as soon as you remember on the same day. Take your next dose at your regularly scheduled time.

    --  If you have difficulty swallowing the tablet whole, talk to your doctor
        about other ways to take XARELTO(®).
    --  Your doctor will decide how long you should take XARELTO(®). Do not
        stop taking XARELTO(®) without talking to your doctor first.
    --  Your doctor may stop XARELTO(®) for a short time before any surgery,
        medical or dental procedure. Your doctor will tell you when to start
        taking XARELTO(®) again after your surgery or procedure.
    --  Do not run out of XARELTO(®). Refill your prescription for XARELTO(®)
        before you run out. When leaving the hospital following a hip or knee
        replacement, be sure that you have XARELTO(®) available to avoid
        missing any doses.
    --  If you take too much XARELTO(®), go to the nearest hospital emergency
        room or call your doctor right away.

WHAT ARE THE POSSIBLE SIDE EFFECTS OF XARELTO(®)?

Please see "What is the most important information I should know about XARELTO(®)?"

Tell your doctor if you have any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. You are also encouraged to report side effects to the FDA: visit http://www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Janssen Pharmaceuticals, Inc., at 1-800-JANSSEN (1-800-526-7736).

Please click here for full Prescribing Information, including Boxed Warnings, and Medication Guide.

Trademarks are those of their respective owners.

Janssen and Bayer together are developing rivaroxaban.

For more information about XARELTO(®), visit www.xarelto.com.

About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us on Twitter at @JanssenUS.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the benefits of XARELTO(®) (rivaroxaban). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC, any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including under "Item 1A. Risk Factors," its most recently filed Quarterly Report on Form 10-Q, including under the caption "Cautionary Note Regarding Forward-Looking Statements," and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Media Contact:
Sarah Freeman
Tel: (215) 510-4758
sfreem21@its.jnj.com

Christina Chan
Tel: (908) 927-5769
Cell: (908) 635-2406
Cchan20@its.jnj.com

Investor Relations Contacts:
Johnson & Johnson
Joseph J. Wolk
Tel: (732) 524-1142

Lesley Fishman
Tel: (732) 524-3922

View original content with multimedia:http://www.prnewswire.com/news-releases/navigate-esus-study-stopped-early-due-to-comparable-efficacy-in-treatment-arms-300532092.html

SOURCE Janssen Research & Development, LLC